Allergen-specific antibodies and T-cell receptors recognizing AllerT4 allergen epitopes

The target Allergen-specific antibodies and T-cell receptors recognizing AllerT4 allergen epitopes refers to the specific repertoire of immune receptors—including Immunoglobulin E (IgE), Immunoglobulin G (IgG), and T-cell receptors (TCRs)—that interact with the epitopes found on the AllerT4 peptide. AllerT4 is a synthetic contiguous overlapping peptide (COP) derived from the sequence of Bet v 1, the primary allergen in birch pollen. In the context of allergen-specific immunotherapy (AIT), these receptors are the functional targets for therapeutic modulation. The primary goal of such therapy is to engage allergen-specific TCRs on CD4+ T cells to induce peripheral tolerance (via anergy or deletion) and to stimulate B cells to produce blocking IgG4 antibodies that compete with IgE for allergen binding. AllerT4 was specifically identified in clinical research as a peptide that, while containing relevant T-cell epitopes, also exhibited residual IgE binding, which can lead to undesirable allergic reactions. Consequently, therapeutic formulations like AllerT were optimized to exclude such peptides in favor of those with lower IgE reactivity. Understanding the interaction between these immune receptors and specific allergen epitopes is crucial for developing safer and more effective peptide-based vaccines for allergic rhinitis and asthma.

Other names

Bet v 1-specific T-cell receptorsBet v 1-specific IgEBet v 1-specific IgGAllerT4-reactive immune receptors

Peptide-based allergen-specific immunotherapy (AIT) aimed at inducing T-cell tolerance and producing blocking IgG4 antibodies to inhibit IgE-mediated allergic responses.